MEDIWOUND LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.77 USD | -7.18% |
|
-1.38% | +55.06% |
| Mar. 21 | MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 | CI |
| Mar. 21 | Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024 |
Presentation Operator MessageOperator (Operator)Good day, and welcome to MediWound's Second Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.77
USD
Average target price
28.5
USD
Spread / Average Target
+80.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.06% | 146M | |
| -5.99% | 83.66B | |
| +2.76% | 40.41B | |
| -24.88% | 28.26B | |
| +53.61% | 24.53B | |
| -8.08% | 16.82B | |
| -33.74% | 13.39B | |
| -16.63% | 11.75B | |
| -11.19% | 11.69B | |
| -2.25% | 8.13B |
- Stock Market
- Equities
- MDWD Stock
- News MediWound Ltd.
- Transcript : MediWound Ltd., Q2 2022 Earnings Call, Aug 09, 2022
